More Pfizer Pfun

The Alt_Mentalities website published a piece, “Lemons into Lemonade: How an off-label marketing fine can be good for business,” tracking Pfizer’s journey through fines for off-label marketing of Neurontin and, later, for Lyrica and other drugs. Punchline question in the piece:

“Was taking the hit for off-label marketing in 2004 all part of a plan to boost sales for forthcoming Lyrica, now the star performer in the Pfizer portfolio?”

And on his Skeptical Sleuth blog for Psychology Today, James C. Coyne, PhD, writes:  “Screening Cancer Patients for Distress: No evidence that screening improves patient outcomes,” – regarding another Pfizer initiative. He begins:

“Pfizer gave a psychologist at the Moffitt Cancer Center in Florida over $10 million to study whether oncology professionals’ attention to cancer patients’ psychological distress could effectively be monitored through chart review. Why this extraordinary amount of money? Is it a matter of generous, unrestricted philanthropy, or is there a clever marketing strategy behind it?”




We Welcome Comments. But please note: We will delete comments that include personal attacks, unfounded allegations, unverified facts, product pitches, profanity or any from anyone who doesn't list what appears to be an actual email address. We will also end any thread of repetitive comments. We don't give medical advice so we won't respond to questions asking for it. Please see more on our comments policy.

Comments are closed.